Darunavir: A Review of Its Use in the Management of HIV-1 Infection
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Darunavir: A Review of Its Use in the Management of HIV-1 Infection
Authors
Keywords
Ritonavir, Atazanavir, Virological Failure, Lopinavir, Amprenavir
Journal
DRUGS
Volume 74, Issue 1, Pages 99-125
Publisher
Springer Nature
Online
2013-12-13
DOI
10.1007/s40265-013-0159-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Assessing Darunavir/Ritonavir—Based Therapy in a Racially Diverse Population: 48-Week Outcomes From GRACE
- (2016) Kimberly Y. Smith et al. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
- Sex-Based Outcomes of Darunavir–Ritonavir Therapy
- (2013) Judith Currier ANNALS OF INTERNAL MEDICINE
- Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients
- (2013) Erkki Lathouwers et al. ANTIVIRAL THERAPY
- Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
- (2013) Kit N. Simpson et al. PHARMACOECONOMICS
- Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients
- (2013) Mabrouk M. Elgadi et al. Drugs in research & development
- Determinants of darunavir cerebrospinal fluid concentrations
- (2012) Andrea Calcagno et al. AIDS
- Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks
- (2012) Judith A. Aberg et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN
- (2012) Denes Banhegyi et al. CURRENT HIV RESEARCH
- Effect of Darunavir on Lipid Profile in HIV-Infected Patients
- (2012) Edgar Turner Overton et al. HIV CLINICAL TRIALS
- Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial
- (2012) C Orkin et al. HIV MEDICINE
- Paediatric HIV - trends & challenges
- (2012) SN Mothi et al. INDIAN JOURNAL OF MEDICAL RESEARCH
- Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients
- (2012) Catherine Fagard et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Antiretroviral Treatment of Adult HIV Infection
- (2012) Melanie A. Thompson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration
- (2012) D. Croteau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Achieving a cure for HIV infection: do we have reasons to be optimistic?
- (2012) V. Le Douce et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- PIN48 Cost-Efectiveness Analysis of Darunavir Versus Atazanavir, Each in Combination With Emtricitabine and Tenofovir, for the Management of Naive Anti-Retroviral HIV Infected Patients, Under the Belgian Social Security Perspective
- (2012) M. Santos et al. VALUE IN HEALTH
- Metabolic effects of atazanavir/ritonavir vs darunavir/ritonavir in combination with tenofovir/emtricitabine in antiretroviral-naïve patients (ATADAR Study)
- (2012) E Martinez et al. Journal of the International AIDS Society
- Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
- (2011) Babafemi Taiwo et al. AIDS
- Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
- (2011) Pedro Cahn et al. AIDS
- Effects of Darunavir/Ritonavir-Based Therapy on Metabolic and Anthropometric Parameters in Women and Men Over 48 Weeks
- (2011) Judith S. Currier et al. AIDS PATIENT CARE AND STDS
- Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacolog
- (2011) Eric Dailly et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96
- (2011) Jan Fourie et al. HIV CLINICAL TRIALS
- Loss of Protease Dimerization Inhibition Activity of Darunavir Is Associated with the Acquisition of Resistance to Darunavir by HIV-1
- (2011) Y. Koh et al. JOURNAL OF VIROLOGY
- PIN82 Cost-Effectiveness of Atazanavir/R Compared to Darunavir/R in Germany
- (2011) P.O. Thuresson et al. VALUE IN HEALTH
- Recent advances in antiretroviral treatment and prevention in HIV-infected patients
- (2011) Fernando Maltêz et al. Current Opinion in HIV and AIDS
- Drug resistance in HIV-1
- (2011) Daniel R Kuritzkes Current Opinion in Virology
- Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men
- (2010) Stephen Taylor et al. AIDS
- Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy
- (2010) S. Lambert-Niclot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Darunavir, Ritonavir, and Etravirine Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-Infected Women
- (2010) Kristine Patterson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy
- (2010) E. Poveda et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients
- (2010) Inge Dierynck et al. ANTIVIRAL THERAPY
- Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment
- (2010) Vanitha Sekar et al. CLINICAL PHARMACOKINETICS
- Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States
- (2010) Anita J. Brogan et al. HIV CLINICAL TRIALS
- Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options
- (2010) S. Naggie et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)
- (2010) C. Delaugerre et al. JOURNAL OF CLINICAL VIROLOGY
- Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition
- (2010) F. Josephson JOURNAL OF INTERNAL MEDICINE
- Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA
- (2010) Josephine Mauskopf et al. PHARMACOECONOMICS
- Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK
- (2010) Karen Moeremans et al. PHARMACOECONOMICS
- US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial
- (2010) Anita Brogan et al. PHARMACOECONOMICS
- Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK
- (2010) Karen Moeremans et al. PHARMACOECONOMICS
- Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009
- (2010) G De La Rosa et al. Journal of the International AIDS Society
- Darunavir
- (2010) Kate McKeage et al. PEDIATRIC DRUGS
- Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
- (2009) Roberto Ortiz et al. AIDS
- Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents
- (2009) Stéphane Blanche et al. AIDS
- Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
- (2009) Anthony M Mills et al. AIDS
- The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
- (2009) Jose R Arribas et al. AIDS
- Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1–Infected Individuals
- (2009) Aylin Yilmaz et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
- (2009) Annemarie M.J. Wensing et al. ANTIVIRAL RESEARCH
- High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial
- (2009) Y. Yazdanpanah et al. CLINICAL INFECTIOUS DISEASES
- Darunavir
- (2009) Kate McKeage et al. DRUGS
- PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection
- (2009) HIV MEDICINE
- Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
- (2009) D. Descamps et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine)
- (2009) Jose R Arribas Current Opinion in HIV and AIDS
- Protease Inhibitor Resistance Update: Where Are We Now?
- (2008) Rose Kim et al. AIDS PATIENT CARE AND STDS
- Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials
- (2008) Sandra de Meyer et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients
- (2008) J. Molto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tipranavir
- (2008) Jennifer S Orman et al. DRUGS
- Conformational Analysis of TMC114, a Novel HIV-1 Protease Inhibitor
- (2008) Kanda Nivesanond et al. Journal of Chemical Information and Modeling
- Lessons from a multicentre paediatric HIV trial
- (2008) Jintanat Ananworanich et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started